Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same authorSame journal

Relacorilant: First Approval.

Drugs·2026

Same author

Rovadicitinib: First Approval.

Drugs·2026

Same author

Sonrotoclax: First Approval.

Drugs·2026

Same author

Copper Histidinate: Pediatric First Approval.

Paediatric drugs·2026

Same author

Correction: Avutometinib and Defactinib: First Approval.

Drugs·2026

Same author

Lerodalcibep: First Approval.

Drugs·2026

Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026

Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026

Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026

Same journal

Linerixibat: First Approval.

Drugs·2026

Same journal

Recaticimab: The First Fc-Engineered PCSK9 Monoclonal Antibody for More Long-Lasting Effect in Lipid Lowering.

Drugs·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 26, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Zenocutuzumab: First Approval.

Hannah A Blair¹

¹Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.

|February 24, 2025

Summary

This summary is machine-generated.

Zenocutuzumab is a new bispecific antibody approved for treating advanced pancreatic cancer or non-small cell lung cancer (NSCLC) with specific gene fusions. This marks a significant advancement for patients with NRG1+ solid tumors who have progressed on prior therapies.

More Related Videos

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Related Experiment Videos

Last Updated: May 26, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Area of Science:

Oncology
Molecular Targeted Therapy
Drug Development

Background:

Zenocutuzumab is an IgG1 bispecific antibody targeting human epidermal growth factor receptor (HER)2 and HER3.
It is developed for solid tumors characterized by neuregulin 1 (NRG1) gene fusions.
NRG1 gene fusions represent a specific molecular alteration driving tumor growth in certain cancers.

Purpose of the Study:

To summarize the key development milestones of zenocutuzumab.
To highlight the regulatory pathway leading to its first approval.
To detail its indication for specific advanced solid tumors.

Main Methods:

Review of preclinical and clinical development data for zenocutuzumab.
Analysis of regulatory submissions and approval processes.
Focus on patient populations with NRG1 gene fusions in pancreatic adenocarcinoma and NSCLC.

Main Results:

Zenocutuzumab received its first US approval on December 4, 2024.
The approval is for adults with advanced, unresectable, or metastatic pancreatic adenocarcinoma or NSCLC.
Patients must have an NRG1 gene fusion and disease progression after prior systemic therapy.

Conclusions:

Zenocutuzumab represents a novel therapeutic option for a genetically defined subset of patients.
This approval signifies a milestone in targeted therapy for NRG1 fusion-positive cancers.
The drug offers a new second-line treatment strategy for advanced pancreatic cancer and NSCLC.